Inhibin is a heterodimeric protein implicated in the regulation of follitropin (FSH) [J_5]4
Comprising an a and either a 13A (inhibin-A) or a PB (inhibin-B) subunit, inhibin is present in the circulation and in follicular fluid in a variety of molecular forms [6, 7] . The amino acid sequences for both subunits are highly conserved with distant species such as goldfish and Xenopus [8] , showing a remarkable degree of conservation of 94% and 96% homology, respectively. Consequently, raising antibodies and developing highly specific assays has proven to he a formidable problem. Compounding this difficulty, the two 3 inhibin subunits show remarkable similarity to a family of growth regulator proteins that, in addition to inhibin and activin, includes transforming growth factor j3, mullerian inhibiting substance (MIS), and fly decapeptide gene complex [9-li] . Existing RIAs have included radiotaheled inhihin or inhibin a fragments as tracer with an anti-a subunit antibody [1] [2] [3] [4] [5] 12, 13] .Because of high concentrations of free a subunit, interpretations based on these assays have been equivocal because the assay detects the biologically inactive free a subunit as well as the biologically active, intact dimer. Needed are specific assays with low limits of detection that can he used to measure circulating, dimeric inhibin concentrations. Previously an ELISA was developed [14] that addressed these problems and enabled estimation of bioactive, dimeric inhihin concentrations. We report here the combination of chemiluminescent detec- After 24 h, the particles were magnetically separated and washed sequentially with three l.0-mL aliquots of assay buffer 1. To each tube was added 400 L of assay buffer 1, followed by 100 tL of anti-a-INH-DMAE.
The tubes were shaken by hand and incubated overnight at room temperature. After 24 h, the tubes were again shaken by hand to resuspend the particles. Separation of the bound antibody complex was performed magnetically, the supernatant was decanted, and the particles washed with a further two 1.0-mL aliquots of assay buffer 1, followed by 1.0 mL of ddH,0.
The tubes were briefly vortex-mixed, 100 jiL of ddH,0 was added, and the tubes were read in an MLA-II by injecting 300 j.L of 0.1 molIL HNO, and 0.5% H,0,, followed by 300 tL of a solution containing the surfactant Arquad at 0.5% (Azko Chemical Co., Chicago, IL) and 0.25 mol/L NaOH, to initiate light emission. The MLA-II was programmed to read for a 2-s integral with data output RLUs. 
Configuration.
To determine how the order of reagent addition and antibody configuration would affect assay results, all four possible assay configurations were explored:
and (
which placed the anti-PA antibody on the solid phase (PMP) followed by washing away all unbound components and subsequent addition of the anti-a antibody, proved to be the best configuration.
This approach eliminated interference of free a-inhibin and provided the lowest limits of detection. Solidphase capture also allowed us to incorporate a wash step after addition of the first antibody. This helped to eliminate saturation of the capture antibody, which resulted in a net decrease in signal (hook effect) and consequently reduced the need to assay samples at multiple dilutions.
ASSAY CHARACTERISTICS
Calibration curve. A log dose-response curve was linear from 100 to 10 000 ng/L (R2 = 0.997), with a minimum detection limit, defined as the concentration that exceeded by 2 SD the mean RLUs of tubes containing no dimeric inhibin-A, of 10 ng/L (1 pg/tube) ( Fig. 1 ). The assay ED50 (the effective dose at which 50% binding occurs) was 42 tg/L and the intraassay CV was 4.3% (n = 10) and 3.3% (n = 10) at mean doses of 570 and 3353 ng/L, respectively. The interassay CV was 10.5% (n = 8). Oxidation of methionine residues of the inhibin dimer has been reported to increase the sensitivity (minimum detectable concentration) of the inhibin-A IRMA [23] . Although this reduced the limit of detection by two-to threefold in the solid-phase immunochemiluminescent assay (SPICA) (inset, Fig. 1 Shown is a dose-response curve for rc-hlNH-A in MultiDiluent (#{149}) subjected to SPICA in the standard oxidized assay format. Inset Compared with unoxidized samples (), preincubation of the serum to be assayed with 1% H202 (#{149}) reduces the limit of detection of the assay. Solid-phase capture at pH 5.0 (#{149}) further reduces the limit of detection. Note that the hINH-Acurve is shown twice.
advantage of the gain, although minimal, this step was incorporated as a routine modification.
pH effects. To determine if any of the binding steps might be affected by hydrogen ion concentration and to optimize the sensitivity, both assay steps were evaluated at a pH of 2.0, 5.0, 7.0, and 10.0. The pH for the PA capture was optimal at pH 5.0 and exhibited a limit of detection of 10.0 ng/L, but at a pH of 7.0 (inset, Fig. 1 ), 2.0, or 10.0 the detection limit was severely attenuated.
The second step of the assay, in which the anti-a antibody was allowed to react, was less sensitive to pH, with changes in pH having almost no effect. Thus, the first step was run at pH 5.0 and the second step at pH 7.0.
Assay cross-reactivity. Virtually no cross-reaction was observed with rc-hFS-288 (10 mg/L),
(hCG; 10 mg/L), or human lutropin (hLH; 10 mgfL), indicating a high specificity of the SPICA (Fig. 2) . rc-hMIS (2 mg/L) tested in subsequent assays also showed no cross-reactivity (data not shown).
Assay inteiference. To study the effects of potential interfering substances on binding of inhibin-A to the antibodies in the assay, we added a variety of peptides and proteins to two doses (50 and 500 ng/L) of inhibin calibrators.
As shown in Serum recovery. Sera were supplemented with 10, 25, 100, and 1000 ng/L rc-hINH-A before measurement in the SPICA. Assay estimates minus concentrations measured in the absence of the added inhibin were used to calculate recovery. Fig. 5 shows the recoveries in serum poo1s from human males and females. Recoveries were parallel to the line representing 100% (P = 0.59 for the female pool and 0.32 for the male pool). Recovery was also estimated with 11 human serum samples spanning various physiological states (normal male as well as female follicular phase, luteal phase, and postmenopausal).
Recoveries at 10 and 100 pg averaged 99% and 111%, respectively.
INHIBIN-A CONCENTRATIONS IN VARIOUS PHYSIOLOGICAL STATES
Human serum samples. Parallelism. When analyzed as described in Materialsand Met/iode, logit-log-transformed dose-response curves of a variety of preparations containing dimeric inhibin-A were parallel to the rc-hINH calibrator (Fig. 4) . These samples included human third-trimester pregnancy serum, human third-trimester pregnancy urine, and serum samples from women (obtained at 5 and 7 days after FSH treatment) during in vitro fertilization (IVF) treatment (P = 0.56 for human pregnancy serum, P = 0.68 for human pregnancy urine, P = 0.50 and 0.70 for IVF serum). Cross-species samples. The SPICA is capable of detecting dimeric inhibin-A in follicular fluids of porcine, ovine, bovine, and human species. These results are summarized in Fig. 7 . Serial dilutions of these follicular fluids resulted in dose-response curves that were parallel to the rc-hINH-A calibration curve over the range of 10-1000 ngfL (P = 0.75 for porcine, 0.06 for ovine, 0.12 for bovine, and 0.09 for human). The SPICA also detects dimeric inhibin-A in serum samples of mouse, rat, and monkey, as well as mouse ovarian, testes, kidney, and placental tissue extracts, and rat ovarian tissue extracts (data not shown).
Molecular variants of bovine inhibin.
Molecular mass variants of purified bovine inhibin were provided by and prepared as described by Good et at. [7] . In brief, bovine follicular fluid was incubated with Affi-Gel 10 linked to affinity-purified bovine anti-bovine a0 Gly-Tyr antibodies. The gel was washed, and the proteins were eluted and subjected to 15% sodium dodecyl sulfate-polyacrylamide gel electrophoresis under nonreducing conditions.
Protein bands were cut from the gel and electroeluted to provide the variants. Dilutions of the resulting molecular variants (32 to >160 Wa) were all immunoreactive in the assay (Fig. 8) , although the preparations were less potent (l0-to l06-fold) than rc-hINIH on a molar basis. Dimeric bovine 32-Wa inhibin showed the greatest reaction. Shown are the calibration curve for rc-hlNH-A (U) and cross-reactivity of various isolated molecular-mass forms of bovine inhibin (29 to >160 kDa) as determined by the SPICA method. Electroeluted BSA was used as a negative control.
Note that the 29-kDa a subunit is not detected.
Discussion
The difficulties in designing a workable immunoassay for inhibin stem from its physiochemistry:
(a)The a and 13subunits are both evolutionarily conserved such that even exposed sites rarely induce production of specific, high-affinity antibodies [24] ; (b)inhibin is highly hydrophobic with potential epitopes buried, and thereby poorly antigenic [25] ; (c) detecting solely the dimer is difficult because inhibins and activins share a common 13subunit, and inhibin exists as both the dimer and free subunit in vivo [1] [2] [3] [4] [5] ; (d)inhibin exists in several different biological forms [6, 7] ; in human follicular fluid this includes a 100-Wa pre-pro-form, a 60-Wa first cleavage form, and the 32-Wa bioactive protein [26] . This diversity has made it difficult to choose, let alone purify, a bioactive inhibin form for generation of antibodies.
cDNA clones encoding the a-and 13-chains of inhibin were isolated in 1985 [27] and 1986 [28] . Antibodies against porcine, bovine, murine, and human inhibin were soon produced and the first RIAs for inhibin developed [12, 13] . These assays included 31-and 58-kDa native bovine inhibin as antigens and 125J labeled 31-Wa bovine inhibin as a tracer. Additional antiinhibin antibodies have been developed against synthetic peptide fragments. The majority of developed antibodies, however, have been to antigenic peptides on the N-terminus of the a-portion of the dimer [1] [2] [3] [4] [5] 12, 13] . Initial studiesaimed at quantifyinginhibinin human follicularfluid [12] , serum, and plasma quicklyled to theoriesabout the role of inhibin in menstrual cycle physiology [1] [2] [3] [4] [5] 29] , during pregnancy [30] [31] [32] ,and even as an ovarian tumor marker [33] . However, in 1988, Robertson et al.compared the bioactivityof inhibin fractionsin an in vitro bioassay with its immunoreactivity in the available RIAs [13] and demonstrated differencesbetween the bio-and immunoactivities.
Subsequently, studies of Robertson et al. [34] and Schneyer et al. [35] documented that the widely used Monash assay was not specific for the dimer but detected inhibin a subunit equally well. This study, coupled with demonstrationsof immunoreactive but not bioactivefragments of inhibinin normal circulation, indicated thatthe a-specific assaycould not be used forspecific detection of dimeric inhibin,and establishedthe need for a two-site inhibinassay.
Shortly thereafter, Knight et al. reported a two-site IRMA involving antibodies raised against synthetic peptidesfrom the 1-32 region of the a subunit and the 82-114 region of the PA-subunit [36] .Although this assay showed low cross-reactivity with free inhibin a subunits, a large discrepancy was observed between bioassay and RIA estimates. Sandwich-method ELISA better accommodated the a-13 two-sitedetectionnecessaryfor accuratedimer quantification [37, 38] . However, immunosorbent assaysdesigned with anu-a-INIH antibodies bound to the plateshowed similarcross-reactivity problems, and the reverse architecture with anti-(3-INH antibodiesas capture antibodies resultedin an insensitive assay.By using an amplifieddetection system and hydrazideplates, Groome overcame theseobstacles [14] and reported an assay specific for the dimeric inhibin-A molecule with detection of 2 ng/L of the 32-Wa inhibin-A dimer [37] .
Building upon similar logic and using the identical pair of monoclonal antibodies but different methodology, this study introduces a SPICA protocol that provides results very similar to Groome's amplified ELISA [14] . By using chemiluminescent detection,this protocol avoids problems inherent with both radioimmunometric and enzyme-linked methods; instead of radioactive tracerswith short shelf-lives and safety hazards, this chemiluminescent procedure involves a stable, innocuous acridinium ester tracer that yields highly sensitive results. The chemiluminescent assay involves fewer steps than the ELISA and eliminates the need for amplification procedures, both of which have the potentialof contributingto higher precision, accuracy,and reproducibility. Since microparticle PMP can be dispensed precisely, variability normally observed in attachment to microplate surfaces is reduced. By keeping particlesin suspension, this approach also overcomes some of the solidphase steric restrictions posed by the ELISA static solidphase,a factor that may improve the valence of second antibody reactions [39] . This protocol,likethatof Groome's ELISA, uses an anti-13 antibody for capture.Free f3-inhibin does not appear to be presentin biological fluidsin high concentrations, as isfree a-inhibin;therefore, anti-13 capture extends the useful range of theassay. The SPICA has been validated forthe measurement of dimericinhibin-Ain serum and shows little cross-reactivity with other members of the TGF-/3 family.In contrastto a previous report [40] ,which indicatedthat introductionof a2-M at 200 mg/L led to a smallunderestimationof inhibin, we have verified that in this format, a2-M at physiological (1 gIL) concentrations does not interfere or cross-react in the assay. In a two-site assay it is imperative that one not only measures the extent to which a related protein is detected, but also the degree to which it interferes with the binding of the intended analyte to eitherof the antibodies. other species, and ability to detect the range of dimeric molecular variants reported here. With this specific assay, serum samples from men, women in the follicular phase, and postmenopausal women contained very little circulating inhibin-A (ator below detectionlimit), as was previously reported by the ELISA [48] .The seeming 10-fold differences in concentrations of inhibin measured by the SPICA and ELISA in men and postmenopausal women are a function of the respective assay sensitivities. Inhibin concentrations were higher in the luteal phase than the follicular phase, confirming earlier observationsof Groome et al. [37] , Lambert-Messerlian et al. [48] ,and Muttukrishna et al. [40] .With the SPICA, dimeric inhibin has been reported to fluctuate episodically during the luteal phase of normally cyclingwomen [49] .As with reports with a-specific assays [31, 32] , samples from pregnant women had the highestconcentrationof dimeric inhibin(-200-fold higher than in normally cycling women during their follicular phase). During IVF treatment, concentrations of dimeric inhibin were -20-fold higher than in normally cycling women, similar to reports with a-specific assays [50] . A 20-fold increasein dimeric inhibinafter6 days of treatmentwith human menopausal gonadotropin has also been reported with Groome's ELISA format [40] . Since changes in dimeric inhibin afterIVF therapy closelyparallelchanges in estradiol [51] , inhibin may be another useful marker for monitoring IVF therapy as previously suggested by McLachlan et al. [52] using an a-directedassay.
In addition to providing a useful means for detecting dimeric inhibin-A in human samples,the SPICA iscapable of measuring inhibin-A in ovine, bovine, and porcine samples, and doseresponse curves with follicular fluidsfrom these specieswere parallel with the rc-hINH-A calibration curve. With the ELISA, the antibodies have been previously shown to recognize human [37, 40, 48] and bovine [7, 53] inhibin forms. The SPICA also detects dimeric inhibin in serum from female rats (N.B. Schwartz, Northwestern Univ., Evanston, IL, unpublished observations) and monkeys [54] . The lower reactivity of bovine inhibin forms, including the 32-kDa form, presumably resultsfrom the few known differ-et al.: Inhibin immunochemiluminescent assay ences in amino acidsequence between the human and bovine a subunit [4] .Five amino acidswithin the region of the potential antibody recognition site differ between human and bovine species. Since the sequence and hence the epitopic site of the PA subunit are identical in both species,the differencein affinity must be due to differences in the amino acid sequence in the a chain [4] .Because the assaydetectsa varietyof molecular mass forms of bovine inhibin, it may also be capable of revealing diverseforms of human inhibin, includingpre-and proproteins in the circulation. Studiesof Muttukrishna et al. [40] involving the ELISA format have indeed demonstrated that the ELISA, which utilizes the same two antibodiesas the SPICA, iscapable of detectinghuman inhibin-Avariantsin the molecular range of Wa.
In this study we used overnight incubation at room temperature. In other experiments, increasing the temperature to 37 #{176}C allowed a significant reductionin incubationtime with no lossof sensitivity (data not shown). Automation of thismodification might permit reporting serum inhibin concentrations with turnaround times as short as 15 mm. With the same PMP and chemiluminescent label, this is done routinely with the Ciba Corning Diagnostics ACS: 180 immunoassay analyzer for a wide range of analytes. Such a development could provide a major impact on monitoring the course of 1VF therapy. In IVF programs, the major cost is the surgicalprocedure, follicular aspiration.
If monitoring of inhibin-A concentrations could occur rapidlyin the clinic, suboptimal cyclescould be canceled for the aspiration procedure,decreasingthe overallcost.
In conclusion,we have developed a two-sitechemiluminescent immunoassay specific for dimeric inhibin-A. This approach was selected to avoid the use of radioactive labels, to reduce the number of steps,and to benefitfrom the ease in detectability of chemiluminescence over the decay of radioiodide, yet retainthe specificity provided by use of two different monoclonal antibodies. The SPICA is sensitive, specific, shows no cross-reactivity, little interference (this is the first assay for inhibin that has addressed interference issues in depth), and is capable of detecting a wide range of molecular variantsof dimeric inhibinin a variety of species and biological fluids. 
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